Kyverna: The Next Big Player in Autoimmune Biotech Sector
Monday, 4 March 2024, 16:26
Morgan Stanley's Bold Forecast
Morgan Stanley projects a substantial surge of over 40% in Kyverna's stock price.
Kyverna's Nasdaq Debut
- On Feb. 8, Kyverna made its stock market debut on Nasdaq and immediately experienced a remarkable 56% surge in its value.
This highlights the rapid growth potential of Kyverna in the competitive biotech sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.